Sign In
Buy TBPH
$15.92
+0.340 (+2.18%)
At Close: Jun 03, 2026
Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & More
01:05pm, Tuesday, 22'nd Feb 2022
Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.
Repligen (RGEN) Q4 Earnings and Revenues Surpass Estimates
03:15pm, Friday, 18'th Feb 2022 Zacks Investment Research
Repligen's (RGEN) fourth-quarter earnings and revenues beat estimates. It expects to achieve revenue growth in the range of 19-24% in 2022.
Wall Street Analysts Think Theravance Bio (TBPH) Could Surge 27%: Read This Before Placing a Bet
03:00pm, Friday, 18'th Feb 2022 Zacks Investment Research
The mean of analysts' price targets for Theravance Bio (TBPH) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a
Wall Street Analysts Think Theravance Bio (TBPH) Could Surge 27%: Read This Before Placing a Bet
11:39am, Friday, 18'th Feb 2022
The mean of analysts' price targets for Theravance Bio (TBPH) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a
Intellia (NTLA) Up on Deal With ONK for Cancer Therapies
04:50pm, Wednesday, 16'th Feb 2022 Zacks Investment Research
Intellia (NTLA) partners with ONK Therapeutics. The collaboration utilises their respective proprietary platforms to develop allogeneic CRISPR-based NK cell therapies for the treatment of cancer.
CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Up Y/Y
04:48pm, Wednesday, 16'th Feb 2022 Zacks Investment Research
CRISPR Therapeutics (CRSP) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.
Zoetis' (ZTS) Q4 Earnings and Revenues Surpass Estimates
05:03pm, Tuesday, 15'th Feb 2022 Zacks Investment Research
Zoetis' (ZTS) earnings and revenues beat estimates for the fourth quarter of 2021.
Tracking Seth Klarman's Baupost Group Holdings - Q4 2021 Update
08:36am, Tuesday, 15'th Feb 2022 Seeking Alpha
Seth Klarman’s 13F portfolio value decreased from $10.88B to $10.13B this quarter. Baupost Group added Fiserv while dropping eBay and International Flavors & Fragrances.
Zacks.com featured highlights include Theravance Biopharma, PattersonUTI Energy and Select Energy Services
03:43pm, Friday, 11'th Feb 2022 Zacks Investment Research
Theravance Biopharma, PattersonUTI Energy and Select Energy Services are included in this blog.
Orphazyme, Y-mAbs Therapeutics top healthcare gainers; ProQR, Senseonics lead losers pack
03:01pm, Friday, 11'th Feb 2022 Seeking Alpha
Gainers: Orphazyme ORPH +22%. Y-mAbs Therapeutics YMAB +11%. Oscar Health (OSCR) +9%. Theravance Biopharma TBPH +9%. VistaGen Therapeutics (VTGN) +8%.Losers: ProQR Therapeutics PRQR -72%
GlaxoSmithKline speculated to be targeting possible acquisition of Theravance Bio
01:15pm, Friday, 11'th Feb 2022 Seeking Alpha
GlaxoSmithKline (GSK) is speculated to be potentially targeting an acquisition of Theravance Biopharma (TBPH). The "rumour mill" is talking about a potential GSK bid for Theravance
3 Best Stocks to Buy Right Away for Earnings Acceleration
02:34pm, Thursday, 10'th Feb 2022 Zacks Investment Research
Invest in Theravance Biopharma (TBPH), PattersonUTI Energy (PTEN) & Select Energy Services (WTTR) at the moment for superb earnings acceleration.
3 Best Stocks to Buy Right Away for Earnings Acceleration
10:46am, Thursday, 10'th Feb 2022
Invest in Theravance Biopharma (TBPH), PattersonUTI Energy (PTEN) & Select Energy Services (WTTR) at the moment for superb earnings acceleration.
Theravance Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022 | MarketScreener
11:01am, Wednesday, 09'th Feb 2022 MarketScreener
DUBLIN, Feb. 9, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. will report its fourth quarter and full year 2021 financial results and provide a business update after market close on Wednesday,… | February 9, 2022
Theravance Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
06:00am, Wednesday, 09'th Feb 2022
DUBLIN, Feb. 9, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2021 financial results and provide a business update after market close on W
